Core Insights - Celanese reported revenue of $2.53 billion for the quarter ended June 2025, a decrease of 4.5% year-over-year, but exceeded the Zacks Consensus Estimate by 1.42% [1] - Earnings per share (EPS) was $1.44, down from $2.38 in the same quarter last year, and surpassed the consensus estimate of $1.38 by 4.35% [1] Financial Performance - Net Sales from the Acetyl Chain were $1.12 billion, exceeding the average estimate of $1.1 billion, but reflecting a year-over-year decline of 7.2% [4] - Net Sales from Inter segment eliminations were reported at -$25 million, worse than the estimated -$20.32 million, but showed a significant year-over-year increase of 38.9% [4] - Net Sales from Engineered Materials reached $1.44 billion, above the average estimate of $1.35 billion, with a slight year-over-year decline of 1.7% [4] - Operating EBITDA for the Acetyl Chain was $260 million, below the average estimate of $287.13 million [4] - Operating EBITDA for Other Activities was -$54 million, slightly better than the average estimate of -$56.51 million [4] - Operating EBITDA for Engineered Materials was $326 million, exceeding the average estimate of $278.5 million [4] Stock Performance - Celanese shares have declined by 21.3% over the past month, contrasting with a 2.7% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]